In the News

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.

Gerstner Sloan Kettering recognizes student research by annually awarding the Grayer Fellowships, the Olayan Fellowship, the Robert B. Catell Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowships.

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.